- Home
- MLCO vs KYMR Comparison
MLCO vs KYMR Comparison
Compare MLCO & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLCO
- KYMR
- Stock Information
- Founded
- MLCO 2004
- KYMR 2015
- Country
- MLCO Hong Kong
- KYMR United States
- Employees
- MLCO N/A
- KYMR N/A
- Industry
- MLCO Hotels/Resorts
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- MLCO Consumer Discretionary
- KYMR Health Care
- Exchange
- MLCO Nasdaq
- KYMR Nasdaq
- Market Cap
- MLCO 2.5B
- KYMR 2.2B
- IPO Year
- MLCO 2006
- KYMR 2020
- Fundamental
- Price
- MLCO $5.45
- KYMR $32.79
- Analyst Decision
- MLCO Buy
- KYMR Buy
- Analyst Count
- MLCO 6
- KYMR 13
- Target Price
- MLCO $7.70
- KYMR $56.69
- AVG Volume (30 Days)
- MLCO 3.7M
- KYMR 748.6K
- Earning Date
- MLCO 04-29-2025
- KYMR 05-01-2025
- Dividend Yield
- MLCO N/A
- KYMR N/A
- EPS Growth
- MLCO N/A
- KYMR N/A
- EPS
- MLCO 0.10
- KYMR N/A
- Revenue
- MLCO $4,638,213,000.00
- KYMR $47,072,000.00
- Revenue This Year
- MLCO $6.59
- KYMR $44.93
- Revenue Next Year
- MLCO $5.00
- KYMR N/A
- P/E Ratio
- MLCO $55.28
- KYMR N/A
- Revenue Growth
- MLCO 22.86
- KYMR N/A
- 52 Week Low
- MLCO $4.78
- KYMR $29.07
- 52 Week High
- MLCO $8.90
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- MLCO 43.11
- KYMR 44.65
- Support Level
- MLCO $5.29
- KYMR $32.08
- Resistance Level
- MLCO $5.64
- KYMR $35.28
- Average True Range (ATR)
- MLCO 0.20
- KYMR 1.79
- MACD
- MLCO -0.01
- KYMR 0.24
- Stochastic Oscillator
- MLCO 24.62
- KYMR 53.52
About MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao with the rest largely from the Philippines as of 2019.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.